‘Freeze-Lock’ cryo label supports the needs of frozen medications

The Freeze-Lock cryo label from Schreiner MediPharm (Oberschleissheim, Germany) is suited for mRNA-based vaccines. The labels also support many cell and gene therapy medications and clinical trials, given their ability to withstand subzero storage and transport temperatures required by pharmaceutical and biopharmaceutical manufacturers and clinical researchers.

Schreiner MediPharm notes that conventional labels fail to offer consistent adhesion. The company’s Freeze-Lock cryo label comprises two interlocking label layers to optimize for adhesive strength and product information readability.

The label includes two components: a bottom and a top label.

The bottom label layer has a microfine surface texture that bonds to a container at room temperature. After being filled with the active ingredient, the label is ready to be stored at subzero temperatures requiring dry ice (–78 °C/–108.4 °F) or liquid nitrogen (–196 °C/–320.8 °F).

The top label layer …

Read more
  • 0

Gene therapy specialist Viralgen opens new facility in Spain’s Basque Country

San Sebastián, Spain–headquartered Viralgen, has opened a new factory in Basque Country in northern Spain.

The company focuses on manufacturing adeno-associated virus (AAV) vectors, which are used in gene therapy and some vaccines.

Since 2018, Viralgen has offered AAV manufacturing for customers working in preclinical through Phase 2 development programs. The company has licensed its Pro10 AAV platform from AskBio.

The first phase of investment in the facility represents a €70 million investment (approximately $83 million). The company plans on spending a total of €120 million (roughly $142 million) after the construction of two additional buildings is completed.

A total of 250 people will work in the facility in 2022. Of that total, some 130 will be new hires.

The inauguration of Viralgen’s new facility occurred on June 30, 2021.

Formed in 2017, Viralgen was a joint venture…

Read more
  • 0